Literature DB >> 27626387

Cancer: Acidic shield puts a chink in p53's armour.

Michelle C Barton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27626387     DOI： 10.1038/nature19469

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

Review 1.  Axin bridges Daxx to p53.

Authors:  Sheng-Cai Lin; Qinxi Li
Journal:  Cell Res       Date:  2007-04       Impact factor: 25.617

Review 2.  Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.

Authors:  Amanda R Wasylishen; Guillermina Lozano
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

3.  The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation.

Authors:  Kurt A Krummel; Crystal J Lee; Franck Toledo; Geoffrey M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

4.  Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Authors:  Mahnaz Janghorban; Amy S Farrell; Brittany L Allen-Petersen; Carl Pelz; Colin J Daniel; Jessica Oddo; Ellen M Langer; Dale J Christensen; Rosalie C Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

5.  Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Authors:  B C Nair; S R Krishnan; G R Sareddy; M Mann; B Xu; M Natarajan; P Hasty; D Brann; R R Tekmal; R K Vadlamudi
Journal:  Cell Death Differ       Date:  2014-05-02       Impact factor: 15.828

6.  SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Authors:  Dale J Christensen; Youwei Chen; Jessica Oddo; Karen M Matta; Jessica Neil; Evan D Davis; Alicia D Volkheimer; Mark C Lanasa; Daphne R Friedman; Barbara K Goodman; Jon P Gockerman; Louis F Diehl; Carlos M de Castro; Joseph O Moore; Michael P Vitek; J Brice Weinberg
Journal:  Blood       Date:  2011-08-15       Impact factor: 22.113

7.  Mutant mice lacking the p53 C-terminal domain model telomere syndromes.

Authors:  Iva Simeonova; Sara Jaber; Irena Draskovic; Boris Bardot; Ming Fang; Rachida Bouarich-Bourimi; Vincent Lejour; Laure Charbonnier; Claire Soudais; Jean-Christophe Bourdon; Michel Huerre; Arturo Londono-Vallejo; Franck Toledo
Journal:  Cell Rep       Date:  2013-06-13       Impact factor: 9.423

Review 8.  Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy.

Authors:  Heidi Olzscha; Semira Sheikh; Nicholas B La Thangue
Journal:  Crit Rev Oncog       Date:  2015

9.  The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo.

Authors:  Pierre-Jacques Hamard; Nicolas Barthelery; Brandon Hogstad; Sathish Kumar Mungamuri; Crystal A Tonnessen; Luis A Carvajal; Emir Senturk; Virginia Gillespie; Stuart A Aaronson; Miriam Merad; James J Manfredi
Journal:  Genes Dev       Date:  2013-09-01       Impact factor: 11.361

10.  Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode.

Authors:  Donglai Wang; Ning Kon; Gorka Lasso; Le Jiang; Wenchuan Leng; Wei-Guo Zhu; Jun Qin; Barry Honig; Wei Gu
Journal:  Nature       Date:  2016-09-14       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.